Results 11 to 20 of about 47,030 (243)

Molecular Mechanisms of the Teratogenic Effects of Thalidomide

Pharmaceuticals, 2020
Thalidomide was sold worldwide as a sedative over 60 years ago, but it was quickly withdrawn from the market due to its teratogenic effects. Thalidomide was later found to have therapeutic effects in several diseases, although the molecular mechanisms ...
Tomoko Asatsuma-Okumura, Takumi Ito, Hiroshi Handa   +2 more
doaj   +2 more sources

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide? [PDF]

Clin Pharmacol Ther
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Burckart GJ, Abdel-Rahman SM, Abulwerdi G, Samuels S, Racz R, Mohamoud MA, Tatonetti NP.   +6 more
europepmc   +2 more sources

Thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF

EMBO Journal, 2021
Thalidomide causes teratogenic effects by inducing protein degradation via cereblon (CRBN)‐containing ubiquitin ligase and modification of its substrate specificity.
S. Yamanaka, Hidetaka Murai, D. Saito, Gembu Abe, Etsuko Tokunaga, T. Iwasaki, Hirotaka Takahashi, H. Takeda, Takayuki Suzuki, N. Shibata, Koji Tamura, T. Sawasaki   +11 more
semanticscholar   +1 more source

Thalidomide: history, withdrawal, renaissance, and safety concerns

Expert Opinion on Drug Safety, 2021
Thalidomide was marketed as a safe and effective sedative beginning in 1957 and was later found to be effective at treating morning sickness. It was believed to be so safe that it was available over the counter in several countries.
N. Vargesson, T. Stephens
semanticscholar   +1 more source

Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand

Journal of Hematology & Oncology, 2010
Background Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients.
Aungchaisuksiri Pantep, Ungkanont Artit, Chuncharunee Suporn, Atichartakarn Vichai, Sorakhunpipitkul Ladda, Niparuck Pimjai, Puavilai Teeraya, Jootar Saengsuree   +7 more
doaj   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis. [PDF]

Int J Dermatol
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Lancz A, Meznerics FA, Árok R, Lengyel AS, Szabó B, Hegyi P, Kiss N, Bánvölgyi A.   +7 more
europepmc   +2 more sources

High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis

Neural Regeneration Research, 2015
Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern.
Hong-xia Xue, Wen-yi Fu, Hua-dong Cui, Li-li Yang, Ning Zhang, Li-juan Zhao   +5 more
doaj   +1 more source

Molecular mechanisms of thalidomide and its derivatives

Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2020
Thalidomide, originally developed as a sedative drug, causes multiple defects due to severe teratogenicity, but it has been re-purposed for treating multiple myeloma, and derivatives such as lenalidomide and pomalidomide have been developed for treating ...
Takumi Ito, H. Handa
semanticscholar   +1 more source

Thalidomide-induced sinus bradycardia in Crohn’s disease: case report and literature review

Journal of International Medical Research, 2019
Thalidomide is effective in inducing and maintaining clinical remission, as well as mucosal healing, in patients with refractory Crohn’s disease (CD).
Menghui Liu, Xiaoqing Lin, Lichun Wang, Yao He, Minhu Chen, Ren Mao   +5 more
doaj   +1 more source

CUL5 is required for thalidomide-dependent inhibition of cellular proliferation. [PDF]

PLoS ONE, 2018
Angiogenesis is essential for cancer metastasis, thus the discovery and characterization of molecules that inhibit this process is important. Thalidomide is a teratogenic drug which is known to inhibit angiogenesis and effectively inhibit cancer ...
Bryan Kunkler, Daniel Salamango, Zachary J DeBruine, Caitlin Ploch, Shirley Dean, David Grossens, Michael P Hledin, Gabriel A Marquez, Julie Madden, Abigayle Schnell, Michael Short, Maria A Burnatowska-Hledin   +11 more
doaj   +1 more source